Basic Information
LncRNA/CircRNA Name | LINC01605 |
Synonyms | NA |
Region | GRCh38_8:37421341-37554183 |
Ensemble | ENSG00000253161 |
Refseq | NR_121620 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | bladder cancer |
ICD-0-3 | C67 |
Methods | qPCR, Western blot |
Sample | bladder cancer tissues, cell lines (EJ, T24, 253j, J82, SV-HUC-1) |
Expression Pattern | up-regulated |
Function Description | LINC01605 was found to be frequently highly expressed in both human BC cells and tissues. Survival analysis indicated that high LINC01605 expression was associated with higher histological grade and clinical stages. down-regulated LINC01605 in BC cells could significantly inhibit the abilities of proliferation, migration, and invasion in vitro. LINC01605 could activate epithelial-mesenchymal transition (EMT) signaling pathway and promote the expression of matrix metallopeptidase (MMP) 9 (MMP9). |
Pubmed ID | 30054424 |
Year | 2018 |
Title | High LINC01605 Expression Predicts Poor Prognosis and Promotes Tumor Progression via Up-Regulation of MMP9 in Bladder Cancer. |
External Links
Links for LINC01605 | GenBank HGNC NONCODE |
Links for bladder cancer | OMIM COSMIC |